

WHAT IS CLAIMED IS:

1. An integration vector capable of site-specific *Listeria* genome integration.
2. The integration vector according to Claim 1, wherein said integration
5 vector is a plasmid.
3. The integration vector according to Claim 2, wherein said integration
vector comprises a bacteriophage integrase gene and a bacteriophage
attachment site.
- 10 4. The integration vector according to Claim 3, wherein said bacteriophage is
a listeriophage.
5. The integration vector according to Claim 3, wherein said attachment site
15 provides for integration at an integration site selected from the group consisting
of: the comK integration site and the tRNA^{Arg} integration site.
6. The integration vector according to Claim 1, wherein said integration
vector further includes a multiple cloning site.
- 20 7. The integration vector according to Claim 6, wherein said integration
vector further includes a coding sequence.
8. The integration vector according to Claim 7, wherein said coding sequence
25 encodes a polypeptide.
9. The integration vector according to Claim 8, wherein said polypeptide is an
antigen.
- 30 10. The integration vector according to Claim 1, wherein said integration
vector is pPL1.
11. The integration vector according to Claim 1, wherein said integration
vector is pPL2.

12. A method of transforming a *Listeria*, said method comprising:
contacting said *Listeria* with an integration vector according to Claim 1
under conditions sufficient for said integration vector to integrate into said
5 *Listeria*'s genome.
13. A *Listeria* transformed with a vector according to Claim 1.
14. A method of eliciting or boosting a cellular immune response to an antigen
10 in a subject, said method comprising:
administering to said subject an effective amount of *Listeria* cells
according to Claim 13.
15. The method according to Claim 14, wherein said *Listeria* cells are
15 attenuated.
16. A vaccine comprising a strain of *Listeria* cells according to Claim 13,
wherein said *Listeria* cells express a heterologous antigen.
- 20 17. The vaccine according to Claim 16, wherein said *Listeria* cells are
attenuated.
18. A recombinant culture of *Listeria* cells according to Claim 13.
- 25 19. The recombinant culture according to Claim 18, wherein said *Listeria* cells
are attenuated.
20. A kit for use in preparing a vector according to Claim 7, said kit
comprising:
30 a vector according to Claim 1; and
at least one nuclease that cuts said vector at said multiple cloning site.
21. The kit according to Claim 20, wherein said kit further comprises a host
cell.

22. A kit for use in preparing a cell according to Claim 13, said kit comprising:
a vector according to Claim 1;
at least one nuclease that cuts said vector at said multiple cloning site; and
5 a *Listeria* cell.

24. A system for preparing a vaccine according to Claim 16, said system
comprising:
a vector according to Claim 1;
10 at least one nuclease that cuts said vector at said multiple cloning site;
a coding sequence for said heterologous antigen;
and
Listeria cells.

15